MN-AYMIUM
9.5.2022 12:02:04 CEST | Business Wire | Press release
Aymium , the leading producer of renewable biocarbon products, announced that it has entered a long-term supply contract for its patented, coal replacement product with Hokuriku Electric Power Company and Nippon Steel Trading . The contract is the largest for advanced biocarbon globally and will support the first large-scale continuous utility use of advanced biocarbon to replace coal in power generation. Aymium produces the only demonstrated carbon-negative product for replacing coal in power generation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005317/en/
“Hokuriku’s pioneering use of Aymium’s leading-edge products to replace coal will accelerate transition away from fossil-fuel-based power generation and reduce environmental impacts,” said Aymium CEO James Mennell . “Aymium’s products allow immediate replacement of coal with a renewable, carbon-negative product. Our collaboration with Hokuriku and Nippon Steel Trading advances our shared mission of decarbonization and global environmental improvement.”
Each ton of Aymium’s product, when used in place of coal, results in a reduction of over 2.5 tons of CO2 as well as over 95% reduction in emission of other pollutants from coal-generated power, including sulfur dioxide and mercury.
The landmark contract and associated environmental benefits were celebrated by U.S. Ambassador to Japan Rahm Emanuel . “Hokuriku Electric Power’s agreement to purchase Aymium’s innovative renewable biocarbon products is a win for U.S. jobs, the environment, and U.S. exports. Japanese investment in Aymium’s innovative technology, from both Hokuriku Electric Power and Nippon Steel Trading, shows the power of U.S. – Japan cooperation,” said Ambassador Emanuel.
Aymium’s renewable product is created through a non-combustion process that converts biomass to high purity biocarbon and biogas, recovers and recycles water from the biomass, and is powered by self-generated renewable energy. The product has been tested at power-plant scale by Hokuriku, confirming suitability and advantages as a replacement for fossil coal.
“Hokuriku is committed to decarbonization, and strengthening our relationship with Aymium, whose patented technology shows high growth potential and contributes to Hokuriku’s efforts to become carbon neutral,” said Mr. Koji Matsuda, Executive President and Representative Director, Hokuriku Electric Power Company.
Hokuriku also announced an equity investment in Aymium. Hokuriku’s investment follows $200 million from investors by major global energy and metals companies with a focus on decarbonization, including Nippon Steel , Rio Tinto and Steel Dynamics .
“As partners to this contract, and investors in Aymium, Nippon Steel Trading is showing its commitment to advance carbon-reduction technologies that will have an immediate and near-term benefit,” said Mr. Yasumitsu Saeki, President and Representative Director, Nippon Steel Trading Corporation. Nippon Steel Trading is acting as Aymium’s and Hokuriku’s trading partner and managing international logistics for the supply to Hokuriku.
Aymium is a Minnesota-based cleantech company that creates renewable products that replace fossil fuels and reduce the environmental impact of large global industries including metals, energy, and crop production. Aymium’s products are protected by more than 275 issued and pending patents globally and are engineered to immediately displace fossil coal in energy production — without the need for any type of plant modifications. Aymium’s patented process converts certified sustainably sourced renewable biomass into biocarbon using integrated thermolysis.
Aymium is constructing two additional production facilities — one in Williams, California, and another in the Pacific Northwest — to produce advanced biocarbon for use by Hokuriku. Aymium anticipates investing over $350 million to construct the facilities that are scheduled to be operational in 2023.
Aymium produces high-value biocarbon and biohydrogen products that can be used to immediately replace fossil fuels in the production of metals, energy, crops, and in the purification of water and air with no modifications to equipment or processes. Produced using sustainably sourced biomass — recovered and unusable wood — Aymium’s bioproducts are renewable, carbon-negative, and they replace emission-heavy fossil fuels such as coal and coke. Aymium’s leading technology is backed by more than 275 issued or pending patents on a global basis. Aymium is headquartered in Minnesota.
About Hokuriku Electric Power Company
Established in 1951, Hokuriku Electric Power Company is a comprehensive energy company that aims to contribute to the development of the Hokuriku region through the stable supply of affordable and high-quality energy. The company's vision for the future is to “develop together with Hokuriku and deliver new value nationwide and overseas,” and it is expanding its business beyond the existing electric power business while contributing to social issues such as addressing the global warming, sustainable development of the region, and the realization of a smart society.
About Nippon Steel Trading Corporation
Nippon Steel Trading Corporation is the core trading company of NIPPON STEEL CORPORATION Group, and was established in October 2013 through the merger of Nippon Steel Trading Co., Ltd. and Sumikin Bussan Corporation. The company continues to grow as a multiple specialty trading company operating four integrated core businesses: steel, industrial supply & infrastructure, textiles, and foodstuffs.
Forward-Looking Statements
This press release contains some predictive statements about future events, including statements related to new facilities and environmental impact. These statements, which are generally preceded or accompanied by such typical conditional words as "anticipate", "intend", "believe", "estimate", "plan", "seek", "project", or "expect", or by the words "may", "will", or "should", are intended to be made as "forward-looking," subject to many risks and uncertainties, within the safe harbor protections of the Private Securities Litigation Reform Act of 1995. These statements speak only as of this date and are based upon currently available information and assumptions, which we consider reasonable as of this date. Such predictive statements are not a guarantee of future performance, and we undertake no duty to update or revise any such statements. There are many factors that could cause such forward-looking statements to turn out differently than anticipated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
